Illumina, Inc. (NASDAQ:ILMN) insider Francis A. Desouza sold 3,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $345.90, for a total value of $1,037,700.00. Following the completion of the transaction, the insider now owns 65,443 shares in the company, valued at approximately $22,636,733.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
ILMN stock opened at $334.32 on Friday. Illumina, Inc. has a twelve month low of $207.51 and a twelve month high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The company has a market capitalization of $49.13 billion, a PE ratio of 83.58, a P/E/G ratio of 2.48 and a beta of 1.09.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.26 by $0.26. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The company had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. During the same quarter last year, the company earned $1.11 earnings per share. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post 5.75 EPS for the current fiscal year.
ILMN has been the topic of several recent research reports. UBS Group initiated coverage on Illumina in a report on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 price target on the stock. Zacks Investment Research lowered Illumina from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. Argus set a $372.00 price target on Illumina and gave the stock a “buy” rating in a report on Friday, August 10th. BidaskClub lowered Illumina from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Finally, Piper Jaffray Companies increased their price target on Illumina to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, October 2nd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Illumina presently has an average rating of “Buy” and a consensus target price of $330.94.
Hedge funds have recently bought and sold shares of the company. Belpointe Asset Management LLC bought a new stake in Illumina during the third quarter worth $155,000. Vanguard Group Inc. lifted its holdings in Illumina by 1.8% during the third quarter. Vanguard Group Inc. now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after acquiring an additional 188,516 shares during the period. Legal & General Group Plc lifted its holdings in Illumina by 6.8% during the third quarter. Legal & General Group Plc now owns 657,774 shares of the life sciences company’s stock worth $241,442,000 after acquiring an additional 41,978 shares during the period. Kepos Capital LP lifted its holdings in Illumina by 394.5% during the third quarter. Kepos Capital LP now owns 12,037 shares of the life sciences company’s stock worth $4,418,000 after acquiring an additional 9,603 shares during the period. Finally, Financial Enhancement Group LLC bought a new stake in Illumina during the third quarter worth $400,000. Institutional investors own 88.91% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Francis A. Desouza Sells 3,000 Shares of Illumina, Inc. (ILMN) Stock” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/12/07/francis-a-desouza-sells-3000-shares-of-illumina-inc-ilmn-stock.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: Trading Strategy Methods and Types
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.